Capital BlueCross coverage for Zepbound (Osa)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 30 or higher
Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Moderate to severe OSA with obesity

All of:

Age >= 18 years
Obesity (BMI >= 30 kg/m2)
Diagnosis of moderate to severe OSA (AHI/REI >= 15 events/hour, or RDI reflecting moderate-severe disease)

Plus any one of:

OSA diagnosis confirmed by attended polysomnography (PSG) with AHI >= 15
OSA diagnosis confirmed by home sleep apnea testing (HSAT) with REI >= 15 (if PSG not indicated or available)
RDI-based diagnosis reflecting clinically significant arousal-predominant obstructive events

Documentation to bring

Diagnosis of moderate to severe OSA (AHI or REI >= 15 events/hour, or equivalent RDI)
OSA diagnostic test result: polysomnography (PSG) preferred, or home sleep apnea test (HSAT) with technically adequate device
BMI documentation >= 30 kg/m2 (obesity)
If HSAT result is negative, inconclusive, or technically inadequate: PSG results required
Documentation confirming OSA is not predominantly central or mixed (< 50% central or mixed apneas/hypopneas)

Not covered when

Craniofacial abnormalities affecting respiration
Predominantly central or mixed sleep apnea (>= 50% central or mixed apneas/hypopneas)
Cheyne-Stokes respiration
Obesity hypoventilation syndrome
Evidence of daytime hypercapnia
Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended

Policy note: FDA-approved for moderate to severe OSA in adults with obesity. The SURMOUNT-OSA program (two phase 3 trials) enrolled participants with mean AHIs of ~50 events/hour and mean BMIs ~39 kg/m2. Trial 1 enrolled participants NOT receiving PAP therapy; Trial 2 enrolled participants already on PAP therapy — indicating PAP trial is NOT required for eligibility. OSA severity grading uses AHI (PSG-derived, preferred), REI (HSAT-based surrogate), or RDI (broader physiologic assessment). The 'moderate to severe' OSA threshold per AASM standards is AHI/REI >= 15 events/hour; the document does not explicitly state a numeric threshold in the criteria section but the FDA indication and SURMOUNT-OSA trial context supports >= 15 as the qualifying threshold. Hypopnea scoring per AASM recommended rule: >= 30% airflow reduction >= 10 seconds with >= 3% O2 desaturation and/or arousal.

Policy effective May 18, 2026 · verified June 5, 2026 · source: Pa policy